New Hologic CEO aims for Dx revenue growth over sale option

On the way in the door as the new CEO of Hologic ($HOLX), Stephen MacMillan said he would oversee further growth of the women's diagnostic medical imaging and surgical products company, despite Hologic's recent efforts to reorganize. With the guiding hand of Carl Icahn, who recently grabbed 12.6% of Hologic's shares, the M&A option was rumored to be on the table, but it looks as if the company will first aim to boost revenue if MacMillan, the former CEO of Stryker ($SYK), can make it happen. More from FierceDiagnostics

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Hand-held ultrasound developer Butterfly Network is going public through a $1.5 billion acquisition deal backed by Glenview Capital.